Inhalation compositions, methods of use thereof, and process for preparation of same

• US 20040023935A1
• Filed: 08/02/2002
• Published: 02/05/2004
• Est. Priority Date: 08/02/2002
• Status: Abandoned Application

• Current Assignee: Dey LP (Pfizer Inc.)
• Original Assignee: Dey LP (Pfizer Inc.)
• Inventors: Banerjee, Partha S., Malladi, Ramana R., Chaudry, Imtiaz A.
• Application Number:
  US10/212,573
• Publication Number:
  US 20040023935A1
• Time in Patent Office: Days
• US Class Current: 514/174
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Bronchodilating concentrates and diluted compositions, methods of use thereof, and processes for making the concentrates and diluted compositions, are provided. The compositions are intended for administration as a nebulized aerosol. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.

Claims

1. A composition, comprising:

(i) a corticosteroid anti-inflammatory agent selected from beclomethasone dipropionate (BDP), beclomethasone monopropionate (BMP), flunisolide, triamcinolone acetonide, ciclesonide, mometasone, mometasone furoate, RPR 106541 having the formula;

 

fluticasone or fluticasone propionate;

(ii) a surfactant;

(iii) an alkali or alkaline earth metal salt at a concentration of about 0.01% to about 0.89% by weight; and

(iv) water.

2. The composition of claim 1, wherein the corticosteroid anti-inflammatory agent is fluticasone or fluticasone propionate.

3. The composition of claim 1, comprising about 1% to about 95% by weight water.

4. The composition of claim 1, comprising about 15% to about 85% by weight water.

5. The composition of claim 1, comprising about 30% to about 80% water.

6. The composition of claim 1, comprising about 5% to about 99% water.

7. The composition of claim 1, comprising about 60% to about 99% water.

8. The composition of claim 1, comprising about 80% to about 99% water.

9. The composition of claim 1, comprising about 40% to about 90% water.

10. The composition of claim 1, comprising about 100 to about 10,000 mcg/mL of the corticosteroid.

11. The composition of claim 1, comprising about 150 to about 4000 mcg/mL of the corticosteroid.

12. The composition of claim 1, comprising about 180 to about 1200 mcg/mL of the corticosteroid.

13. The composition of claim 1, comprising about 10 to about 2000 mcg/mL of the corticosteroid.

14. The composition of claim 1, comprising about 15 to about 1000 mcg/mL of the corticosteroid.

15. The composition of claim 1, comprising about 30 to about 300 mcg/mL of the corticosteroid.

16. The composition of claim 1, wherein the surfactant is a high-hydrophilic-lipophilic balance (HLB) surfactant.

17. The composition of claim 16, wherein the HLB of the surfactant is greater than about 10.

18. The composition of claim 1, comprising about 3% to about 85% by weight of a high-HLB surfactant.

19. The composition of claim 18, wherein the high-HLB surfactant is an ethoxylated derivative of vitamin E.

20. The composition of claim 19, wherein the high-HLB surfactant is tocopheryl polyethylene glycol 1000 succinate (TPGS).

21. The composition of claim 1, comprising about 5% to about 50% by weight of a high-HLB surfactant.

22. The composition of claim 1, comprising about 10% to about 40% by weight of a high-HLB surfactant.

23. The composition of claim 1, comprising about 12% to about 40% by weight of a high-HLB surfactant.

24. The composition of claim 1, comprising about 0.3% to about 25% by weight of a high-HLB surfactant.

25. The composition of claim 1, comprising about 0.5% to about 12% by weight of a high-HLB surfactant.

26. The composition of claim 1, comprising about 1% to about 10% by weight of a high-HLB surfactant.

27. The composition of claim 1, wherein the alkaline earth metal salt is a halide selected from magnesium and calcium halides.

28. The composition of claim 1, wherein the alkaline earth metal salt is magnesium chloride or calcium chloride.

29. The composition of claim 1 that comprises an alkali metal salt.

30. The composition of claim 29, wherein the alkali metal salt is a halide selected from sodium, lithium, and potassium halides.

31. The composition of claim 1, wherein the alkali metal salt is sodium chloride, lithium chloride or potassium chloride.

32. The composition of claim 1, wherein the alkali metal salt is sodium chloride.

33. The composition of claim 1, comprising about 0.01% to about 0.89% by weight of the alkali or alkaline earth metal salt.

34. The composition of claim 1, comprising about 0.1% to about 0.7% by weight of the alkali or alkaline earth metal salt.

35. The composition of claim 1, comprising about 0.4% or 0.5% to about 0.65% by weight of the alkali or alkaline earth metal salt.

36. The composition of claim 1, comprising about 0.6% by weight of an alkali or alkaline earth metal salt.

37. The composition of claim 1, comprising about 0.01% to about 0.6% by weight of the alkali or alkaline earth metal salt.

38. The composition of claim 1, comprising about 0.05% to about 0.45% by weight of an alkali or alkaline earth metal salt.

39. The composition of claim 1, comprising about 0.05% to about 0.3% by weight of the alkali or alkaline earth metal salt.

40. The composition of claim 1, comprising about 0.05% to about 0.2% by weight of the alkali or alkaline earth metal salt.

41. The composition of claim 1, comprising about 0.1% by weight of the alkali or alkaline earth metal salt.

42. The composition of claim 1, comprising about 0.45% by weight of the alkali or alkaline earth metal salt.

43. The composition of claim 1, further comprising a buffer.

44. The composition of claim 43, wherein the buffer is citric acid/phosphate, acetate, barbital, borate, Britton-Robinson, cacodylate, citrate, collidine, formate, maleate, Mcllvaine, phosphate, Prideaux-Ward, succinate, citrate-phosphate-borate (Teorell-Stanhagen), veronal acetate, MES (2-(N-morpholino)ethanesulfonic acid), BIS-TRIS (bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane), ADA (N-(2-acetamido)-2-iminodiacetic acid),ACES (N-(carbamoylmethyl)-2-aminoethanesulfonaic acid), PIPES (piperazine-N,N′

-bis(2-ethanesulfonic acid)), MOPSO (3-(N-morpholino)-2-hydroxypropanesulfonic acid),BIS-TRIS PROPANE (1,3-bis(tris(hydroxymethyl)methylamino)propane), BES (N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonaic acid), MOPS (3-(N-morpholino)propanesulfonic acid), TES (N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid), HEPES (N-(2-hydroxyethyl)piperazine-N′

-(2-ethanesulfonic acid), DIPSO (3-(N,N-bis(2-hydroxyethyl)amino)-2-hydroxypropanesulfonic acid), MOBS (4-(N-morpholino)butanesulfonic acid), TAPSO (3-(N-tris(hydroxymethyl)methylamino)-2-hydroxypropanesulfonic acid), TRIZMA®

(tris(hydroxymethylaminomethane), HEPPSO (N-(2-hydroxyethyl)piperazine-N′

-(2-hydroxypropanesulfonic acid), POPSO (piperazine-N,N′

-bis(2-hydroxypropanesulfonic acid)), TEA (triethanolamine), EPPS (N-(2-hydroxyethyl)piperazine-N′

-(3-propanesulfonic acid), TRICINE (N-tris(hydroxymethyl)methylglycine), GLY-GLY (glycylglycine), BICINE (N,N-bis(2-hydroxyethyl)glycine), HEPBS (N-(2-hydroxyethyl)piperazine-N′

-(4-butanesulfonic acid)), TAPS (N-tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid), or AMPD (2-amino-2-methyl-1,3-propanediol).

45. The composition of claim 43, wherein the buffer is citric acid/phosphate buffer, acetate buffer, citrate buffer or phosphate buffer.

46. The composition of claim 43, wherein the buffer is a citrate buffer (citric acid/sodium citrate).

47. The composition of claim 43, wherein the buffer concentration is about 0.1 mM to about 100 mM.

48. The composition of claim 43, wherein the buffer concentration is about 1 mM to about 50 mM.

49. The composition of claim 43, wherein the buffer concentration is about 5 mM to about 25 mM.

50. The composition of claim 43, wherein the buffer concentration is about 0.01 mM to about 25 mM.

51. The composition of claim 43, wherein the buffer concentration is about 0.1 mM to about 10 mM.

52. The composition of claim 43, wherein the buffer concentration is about 1 mM to about 5 mM.

53. The composition of claim 1, further comprising an excipient or additive.

54. The composition of claim 53, wherein the excipient or additive is a stabilizer, complexing agent, antioxidant, preservative, flavoring or vitamin.

55. The composition of claim 54, wherein the complexing agent is ethylenediaminetetraacetic acid (EDTA) or a salt thereof.

56. The composition of claim 54, wherein the complexing agent is EDTA.

57. The composition of claim 54, wherein the preservative is benzalkonium chloride, benzoic acid, or sodium benzoate.

58. The composition of claim 54, wherein the antioxidant is a vitamin, provitamin, ascorbic acid, vitamin E or salts or esters thereof.

59. The composition of claim 54, wherein the stabilizer is ferric citrate, ferric phosphate or ferric pyrophosphate.

60. The composition of claim 1, further comprising a cosolvent.

61. The composition of claim 60, wherein the cosolvent is a hydroxylated solvent.

62. The composition of claim 60, wherein the cosolvent is an alcohol or a glycol.

63. The composition of claim 60, wherein the cosolvent is isopropyl alcohol, propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol, or a polyoxyethylene alcohol.

64. The composition of claim 60, wherein the cosolvent is a glycol.

65. The composition of claim 60, wherein the cosolvent is propylene glycol or polyethylene glycol

66. The composition of claim 60, wherein the cosolvent is polyethylene glycol 300 or 400.

67. The composition of claim 60, wherein the cosolvent is a glycol at a concentration of about 0% to about 50% by weight.

68. The composition of claim 60, wherein the cosolvent is a glycol at a concentration of about 1% to about 40% by weight.

69. The composition of claim 60, wherein the cosolvent is a glycol at a concentration of about 6% to about 20% by weight.

70. The composition of claim 60, wherein the cosolvent is propylene glycol.

71. The composition of claim 60, wherein the cosolvent is a glycol at a concentration of about 0% to about 15% by weight.

72. The composition of claim 60, wherein the cosolvent is a glycol at a concentration of about 0.1% to about 10% by weight.

73. The composition of claim 60, wherein the cosolvent is a glycol at a concentration of about 1% to about 4 or 5% by weight.

74. The composition of claim 1, further comprising an emulsifier.

75. The composition of claim 74, wherein the emulsifier is polyoxyetheylene sorbitan fatty esters or polysorbates, including, but not limited to, polyethylene sorbitan monooleate (Polysorbate 80), polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polysorbate 65 (polyoxyethylene (20) sorbitan tristearate), polyoxyethylene (20) sorbitan mono-oleate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate;

lecithins;

alginic acid;

sodium alginate;

potassium alginate;

ammonium alginate;

calcium alginate;

propane-1,2-diol alginate;

agar;

carrageenan;

locust bean gum;

guar gum;

tragacanth;

acacia;

xanthan gum;

karaya gum;

pectin;

amidated pectin;

ammonium phosphatides;

microcrystalline cellulose;

methylcellulose;

hydroxypropylcellulose;

hydroxypropylmethylcellulose;

ethylmethylcellulose;

carboxymethylcellulose;

sodium, potassium and calcium salts of fatty acids;

mono- and di-glycerides of fatty acids;

acetic acid esters of mono- and di-glycerides of fatty acids;

lactic acid esters of mono- and di-glycerides of fatty acids;

citric acid esters of mono- and di-glycerides of fatty acids;

tartaric acid esters of mono- and di-glycerides of fatty acids;

mono- and diacetyltartaric acid esters of mono- and di-glycerides of fatty acids;

mixed acetic and tartaric acid esters of mono- and di-glycerides of fatty acids;

sucrose esters of fatty acids;

sucroglycerides;

polyglycerol esters of fatty acids;

polyglycerol esters of polycondensed fatty acids of castor oil;

propane-1,2-diol esters of fatty acids;

sodium stearoyl-2-lactylate;

calcium stearoyl-2-lactylate;

stearoyl tartrate;

sorbitan monostearate;

sorbitan tristearate;

sorbitan monolaurate;

sorbitan mono-oleate;

sorbitan monopalmitate;

extract of quillaia;

polyglycerol esters of dimerised fatty acids of soya bean oil;

oxidatively polymerised soya bean oil;

or pectin extract.

76. The composition of claim 1, further comprising glycerin.

77. The composition of claim 76, comprising about 0% to about 50% by weight glycerin.

78. The composition of claim 76, comprising about 1% to about 40% by weight glycerin.

79. The composition of claim 76, comprising about 6% to about 20% by weight glycerin.

80. The composition of claim 76, comprising about 0% to about 15% by weight glycerin.

81. The composition of claim 76, comprising about 1% to about 10% by weight glycerin.

82. The composition of claim 76, comprising about 1% to about 5% by weight glycerin.

83. The composition of claim 1, comprising about 1% to about 69% by weight water.

84. The composition of claim 1, comprising about 15% to about 69% by weight water.

85. The composition of claim 1, comprising about 30% to about 69% by weight water.

86. The composition of claim 1, comprising about 5% to about 69% by weight water.

87. The composition of claim 1, comprising about 60% to about 69% by weight water.

88. The composition of claim 1, comprising about 40% to about 69% by weight water.

89. The composition of claim 1 that has been nebulized.

90. A kit, comprising (a) a composition of claim 1;

and (b) a nebulizer.

91. An article of manufacture, comprising packaging material, a composition of claim 1, which is useful for treatment, prevention or amelioration of one or more symptoms of diseases or disorders associated with undesired and/or uncontrolled bronchoconstriction, and a label that indicates that the composition is used for treatment, prevention or amelioration of one or more symptoms of diseases or disorders associated with undesired and/or uncontrolled bronchoconstriction.

92. A method for treating, preventing, or ameliorating one or more symptoms of a bronchoconstrictive disorder, comprising administering a composition of claim 1 to a subject in need thereof.

93. The method of claim 92, wherein the bronchoconstrictive disorder is asthma, bronchial asthma, allergic asthma, intrinsic asthma, late asthma, airway hyper-responsiveness, or chronic bronchitis.

94. The method of claim 92, wherein the composition is administered via oral inhalation or nasally.

95. The method of claim 92, further comprising administering one or more of (a) or (b) as follows:

(a) a β

₂-adrenoreceptor agonist;

or (b) a dopamine (D₂) receptor agonist;

simultaneously with, prior to or subsequent to the composition provided herein.

96. The method of claim 95, wherein the _β

2-adrenoreceptor agonists is Albuterol (α

¹-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol);

Bambuterol (dimethylcarbamic acid 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,3-phenylene ester);

Bitolterol (4-methylbenzoic acid 4-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,2-phenylene ester);

Broxaterol (3-bromo-α

-(((1,1-dimethylethyl)amino)methyl)-5-isoxazolemethanol);

Isoproterenol (4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol);

Trimetoquinol (1,2,3,4-tetrahydro-1-((3,4,5-trimethoxyphenyl)methyl)-6,7-isoquinolinediol);

Clenbuterol (4-amino-3,5-dichloro-α

-(((1,1-diemthylethyl)amino)methyl)benzenemethanol);

Fenoterol (5-(1-hydroxy-2-((2-(4-hydroxyphenyl)-1-methylethyl)amino)ethyl)-1,3-benzenediol);

Formoterol (2-hydroxy-5-((1RS)-1-hydroxy-2-(((1RS)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide);

(R,R)-Formoterol;

Desformoterol ((R,R) or (S,S)-3-amino-4-hydroxy-α

-(((2-(4-methoxyphenyl)-1-methylethyl)amino)methyl)benzenemethanol);

Hexoprenaline (4,4′

-(1,6-hexanediyl)-bis(imino(1-hydroxy-2,1-ethanediyl)))bis-1,2-benzenediol);

Isoetharine (4-(1-hydroxy-2-((1-methylethyl)amino)butyl)-1,2-benzenediol);

Isoprenaline (4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol);

Metaproterenol (5-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-1,3-benzenediol);

Picumeterol (4-amino-3,5-dichloro-_α

-(((6-(2-(2-pyridinyl) ethoxy)hexyl)amino)methyl)benzenemethanol);

Pirbuterol (_α

⁶-(((1,1-dimethylethyl)amino)methyl)-3-hydroxy-2,6-pyridinemethanol);

Procaterol (((R*,S*)-(±

)-8-hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone);

Reproterol ((7-(3-((2-(3,5-dihydroxyphenyl)-2-hydroxyethyl)amino)propyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione);

Rimiterol (4-(hydroxy-2-piperidinylmethyl)-1,2-benzenediol);

Salbutamol ((±

)-á

¹-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol);

(R)-Salbutamol;

Salmeterol ((±

)-4-hydroxy-α

¹-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol);

(R)-Salmeterol;

Terbutaline (5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,3-benzenediol);

Tulobuterol (2-chloro-α

-(((1,1-dimethylethyl)amino)methyl)benzenemethanol);

or TA-2005 (8-hydroxy-5-((1R)-1-hydroxy-2-(N-((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)carbostyril hydrochloride); and

the dopamine (D₂) receptor agonist is Apomorphine ((R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol);

Bromocriptine ((5′

α

)-2-bromo-12′

-hydroxy-2′

-(1-methylethyl)-5′

-(2-methylpropyl)ergotaman-3′

,6′

,18-trione);

Cabergoline ((8â

)-N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)ergoline-8-carboxamide);

Lisuride (N′

-((8α

)-9,10-didehydro-6-methylergolin-8-yl)-N,N-diethylurea), Pergolide ((8α

)-8-((methylthio)methyl)-6-propylergoline);

Levodopa (3-hydroxy-L-tryrosine);

Pramipexole ((S)-4,5,6,7-tetrahydro-N⁶-propyl-2,6-benzothiazolediamine);

Quinpirole hydrochloride (trans-(−

)-4aR-4,4a,5,6,7,8,8a,9-octahydro-5-propyl-1H-pyrazolo[3,4-g]quinoline hydrochloride);

Ropinirole (4-(2-(dipropylamino)ethyl)-1,3-dihydro-2H-indol-2-one); and

Talipexole (5,6,7,8-tetrahydro-6-(2-propenyl)-4H-thiazolo[4,5-d]azepin-2-amine).

97. The method of claim 92, further comprising administering one or more of the following:

an IL-5 inhibitor;

an antisense modulators of IL-5;

milrinone;

milrinone lactate;

a tryptase inhibitor;

a tachykinin receptor antagonist;

a leukotriene receptor antagonist;

a 5-lypoxygenase inhibitor, or an anti-IgE antibody.

98. A process for preparing the composition of claim 1, comprising:

(a) dissolving the corticosteroid in the surfactant;

(b) dissolving the alkali or alkaline earth metal halide in the water;

(c) adding the corticosteroid/surfactant solution slowly to the alkali or alkaline earth metal halide/water solution.

99. The process of claim 98, further comprising adding a cosolvent to the surfactant prior to step (a).

100. The process of claim 98, wherein the corticosteroid/surfactant solution is maintained above about 45°

C.

101. The process of claim 98, wherein the corticosteroid/surfactant solution is maintained above about 60°

C.

102. The process of claim 98, wherein the sodium chloride/water solution is maintained at about ambient temperature.

103. The process of claim 98, further comprising:

(d) filtering the solution resulting from step (c).

104. The process of claim 103, wherein the pore size of the filter is equal to or less than about 0.22 μ

m.

105. The process of claim 103, wherein the pore size of the filter is equal to or less than about 0.1 μ

m.

106. The process of claim 98, further comprising addition of one or more of (i) buffer, (ii) ferric citrate or (iii) glycerin to the aqueous phase prior to step (c).

108. A combination, comprising a composition of claim 1 and a diluent.

107. A composition, comprising a corticosteroid anti-inflammatory agent and an alkali or alkaline earth metal halide, wherein the alkali or alkaline earth metal halide is present at a concentration of about 0.01% to about 0.89% by weight.